Pfiz­er and Bio­haven bring rimegepant to Eu­rope as mi­graine war with Ab­b­Vie heats up

Ab­b­Vie’s been crank­ing up the heat on Bio­haven’s oral mi­graine med Nurtec with its ri­val Qulip­ta. Bio­haven’s so­lu­tion? Take the com­pe­ti­tion over­seas.

Nurtec — or rimegepant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER